glp-1 dpp 4 PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: DPP4 Role of DPP-4 Inhibitors in

Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia

A multidisciplinary approach also involves mental health professionals to address the complex needs that patients may have during their treatment

Ask them where they suggest their patients purchase these drugs

DOI: 10.4102/jmh.v7i1.97 [Google Scholar] Philp AM, Butterworth S, Davis ET, Jones SW